Free Trial
NYSE:CTLT

Catalent Q1 2025 Earnings Report

Catalent EPS Results

Actual EPS
-$0.13
Consensus EPS
$0.05
Beat/Miss
Missed by -$0.18
One Year Ago EPS
-$0.10

Catalent Revenue Results

Actual Revenue
$1.02 billion
Expected Revenue
$1.06 billion
Beat/Miss
Missed by -$35.40 million
YoY Revenue Growth
+4.20%

Catalent Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, November 5, 2024
Conference Call Time
7:00AM ET

Catalent Earnings Headlines

Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMI
Lisata Therapeutics signs research license with Catalent
Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
Catalent Announces New Board Appointments
See More Catalent Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Catalent? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Catalent and other key companies, straight to your email.

About Catalent

Catalent (NYSE:CTLT), together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

View Catalent Profile

More Earnings Resources from MarketBeat